Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study
Aug 2026· Breast Cancer Research and Treatment· Vol 219· 0 citations· 26 references
Medicine
TL;DR
Camrelizumab plus apatinib demonstrated manageable toxicity and preliminary antitumor activity, supporting further investigation of this chemotherapy-free strategy in early-stage TNBC patients with enriched TILs.
PURPOSE
To evaluate the efficacy, safety, and tumour microenvironment remodelling of neoadjuvant camrelizumab plus apatinib in resectable head and neck squamous cell carcinoma (HNSCC; stage II-IVA).
MATERIALS AND METHODS
In this single-arm, exploratory phase II trial (ChiCTR2100051989), 41 patients with resectable HN...
Ya-Qiong Jie, Zhuo Chen, Li-Huang Chen et al.· Clinical Cancer Research· 0 citations
Background: triple-negative breast cancer (TNBC) is associated with aggressive tumor biology and limited systemic treatment options.
Incorporation of platinum agents into neoadjuvant chemotherapy (NACT) can increase pathological complete response (pCR) rates, but platinum-based regimens containing anthracyclines are of...
E. Ratova, L. Bolotina, A. Kaprin· Russian Medical Inquiry· 0 citations
This multicohort, single-center, phase II trial explored the efficacy and safety of a biomarker-driven total neoadjuvant therapy (TNT) regimen in high-risk locally advanced rectal cancer (LARC) patients. The regimen included induction chemotherapy (4 cycles of mFOLFOX6) with targeted agents (bevacizumab for cohort B an...
T. Ma, Jingyi Liu, Sen Zhang et al.· Signal Transduction and Targ...· 0 citations
Purpose Chemo-immunotherapy has demonstrated significant survival benefits in non-small cell lung cancer. However, real-world data on its effectiveness and safety in patients with unresectable stage III–IV disease remain insufficient. Furthermore, whether the addition of anti-angiogenic agents provides additional benef...
Anthracycline-free regimens have attracted growing interest because of less cardiac toxicity, especially in HER2-positive breast cancer when used in combination with trastuzumab and pertuzumab. This prospective, single-center trial (NEOPATH) aimed to assess the efficacy and safety of nab-paclitaxel combined with carbop...
Jia-Yi Wu, Deyue Liu, Mengdi Chen et al.· International Journal of Can...· 0 citations
AIM
To evaluate the real‑world efficacy and safety of adding programmed cell death protein 1 (PD-1) inhibitors to neoadjuvant chemotherapy in Chinese patients with triple‑negative breast cancer (TNBC).
PATIENTS AND METHODS
This single-center retrospective study enrolled 218 TNBC patients receiving neoadjuvant therapy...
Ruo-Xi Xu, Pin-Chao Fan, Yi-Qiu Liu et al.· Immunotherapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
